ICU Medical Inc stock (US44930G1076): analyst sentiment and targets in focus after recent trading around USD 135

ICU Medical Inc shares on Nasdaq have been trading around USD 135 in recent sessions, putting renewed attention on Wall Street analyst ratings and 12-month price targets for the United States-based infusion therapy specialist.

ICU Medical Inc shares on the Nasdaq under the ticker ICUI most recently closed at about USD 135.39 on 05/29/2026, highlighting a phase of consolidation for the United States-based medical technology group and drawing fresh attention to current analyst expectations for the stock, according to MarketBeat as of 05/29/2026 (MarketBeat as of 05/29/2026).

The stock is listed on Nasdaq in the United States, where healthcare and medtech names remain a key component of major indices, and ICUI has also seen interest from European investors who trade the shares over the counter on German platforms such as Tradegate in euros, based on data from German trading venues as of late May 2026.

The stock traded at 135.39 USD on 05/29/2026 on Nasdaq, according to MarketBeat as of 05/29/2026.

As of: 01.06.2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: ICUI
• Sector/industry: Medical technology, infusion therapy and critical care devices
• Headquarters/country: San Clemente, United States
• Core markets: North America, Europe and selected international healthcare markets
• Key revenue drivers: Infusion therapy systems, vascular access devices and critical care consumables and equipment used in hospitals and other care settings
• Home exchange/listing venue: Nasdaq (ICUI)
• Trading currency: USD

ICU Medical Inc: core business model

ICU Medical Inc focuses on designing and supplying infusion therapy, vascular access and critical care devices for hospitals and other healthcare providers worldwide, with sales primarily generated from recurring demand for consumables and related equipment used in these therapies.

What banks and research houses say about ICU Medical Inc

Analyst attention on ICU Medical Inc has been steady, with data compiled by MarketBeat indicating that six Wall Street equity research analysts currently follow the stock and have issued 12-month price targets and ratings within the past year (MarketBeat as of 05/29/2026).

According to MarketBeat as of 05/29/2026, the consensus across six analysts is a 12-month price target of USD 168.00 for ICU Medical Inc, with a high estimate of USD 180.00 and a low estimate of USD 163.00, and the rating distribution includes one sell rating, three buy ratings and two strong buy ratings for ICUI shares (MarketBeat as of 05/29/2026).

Conclusion

The latest trading level of ICU Medical Inc shares around USD 135.39 on Nasdaq, combined with active analyst coverage, keeps the United States-listed medtech company on the radar of investors tracking healthcare equipment names.

With a consensus 12-month price target of USD 168.00 from six analysts and a mix of sell, buy and strong buy ratings, the market continues to receive a broad range of views on the companys prospects in infusion therapy and critical care segments, which may influence how investors interpret future newsflow and financial results.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.